Sponsored Satellite Program: Making Sense of Omega-3 Headlines: Recent Evidence on Cardiovascular Outcomes and Public Health Implications
Sponsored By: DSM
Over the past several decades, a great deal of research has investigated the effects of omega-3 EPA and DHA on cardiovascular health and mortality. Several authoritative statements have been issued by regulatory agencies and scientific societies, based on the body of evidence linking intake of EPA and DHA to reduced cardiovascular disease risk. However, equivocal results in some recent clinical trials have created confusion about this relationship. The publication of three large trials (ASCEND, REDUCE-IT and VITAL) between 2018 and 2019 has greatly increased the evaluable body of clinical evidence. A recent meta-analysis of supplementation trials, including these three large trials, reported that EPA and DHA positively impacted several important cardiovascular outcomes in a dose-response manner. Pharmaceutical doses of EPA and DHA, or EPA alone, have been shown to be an effective treatment for hypertriglyceridemia but some recent results have been inconsistent. In this session we will explore the public health implications of these findings and discuss whether it is time to establish a DRI for long-chain omega-3 fatty acids based on this new evidence.
This Sponsored Satellite Program was presented at NUTRITION 2020 LIVE ONLINE.
This Sponsored Satellite Program includes the following presentations:
- History of Omega-3 Recommendations in Cardiovascular Health and Disease
- How VITAL are Omega-3s for Heart Health? The VITAL Trial and Updated Meta-Analysis
- Recent Clinical Evidence on EPA and DHA for CV Risk Reduction: Clinical Considerations
- Panel Discussion
- 1.50 Attendance
Learners are eligible to download a Certificate of Attendance upon activity completion. A Certificate of Attendance confirms the learner has completed the activity and does not confer any continuing education credit to the learner from ASN.